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Summary 
Superantigens (SAGs) represent a new class of antigens, characterized as T cell receptor (TCR) 
V3-reactive elements. Bacterial toxins constitute the major group of exogenous SAGs, while 
the mouse mammary tumor virus (MMTV)-encoded Mls molecules represent the endogenous 
SAGs. Mls-1 is the prototype of the latter SAGs, because it elicits a very potent T cell stimulatory 
response in vitro in unprimed T cells expressing the TCR V3 6 or 8.1 chains. In vivo, Mls-1 
causes deletion of immature T cells bearing the VB 6, 7, 8.1, or 9 chains. Although Mls-1 was 
functionally discovered  >20 yr ago, it has not been possible to raise antibodies against this molecule. 
We have previously cloned and sequenced the Mtv-7 sag gene, which encodes Mls-1. Sequence 
comparisons with other MMTV sag genes suggested that the polymorphic 3' end encodes the 
TCR V3 specificity of these SAGs. We have, therefore, immunized hamsters with a 14-amino 
acid peptide from the deduced COOH-terminal sequence of the Mtv-7 sag gene. We describe 
here the production of a monodonal antibody (mAb), 3B12, which is peptide specific and reacts 
with a recombinant baculovirus product of Mtv-7 sag.  This mAb blocks Mls-l-specific T  cell 
recognition and detects the Mls-1 protein on the surface of the B cell hybridoma LBB.A, but 
not on LBB.11, which is an Mtv-7 loss variant of LBB.A. Transfection of the Mtv-7 sag gene 
into LBB.11 renders this cell functionally Mls-1  + as well as positive for 3B12 binding, confirming 
the specificity of this mAb. It is well documented that B cells and CD8 + T cells express T cell 
stimulatory Mls-1 determinants,  and we show here that this functional profile correlates with 
the expression of MMTV-specific mRNA. However, primary lymphocytes derived from Mls-1 § 
mice do not stain with 3B12, even after in vitro activation with mitogens or phorbol ester. 
number of  bacterial and viral proteins have been classified 
recently as superantigens (SAGs)  1 (1-6). The hallmark 
of a SAG is the ability to stimulate a significant proportion 
of naive T lymphocytes. While conventional antigens are rec- 
ognized by the TCR antigen recognition site, SAGs interact 
primarily with particular  V3 chains of the TCR (7). Fur- 
thermore, SAGs are not processed into peptides (8) and are 
believed to associate with MHC class II molecules outside 
the peptide binding groove (9). 
A number of groups have shown that the retrovirus mouse 
mammary tumor  virus  (MMTV)  encodes  a  SAG  (4-6). 
MMTVs exist as both exogenous infectious viruses and as 
endogenous inherited elements in the germline.  About 20 
polymorphic endogenous MMTVs have been found in mice. 
The MMTV SAG is encoded within the U3 region of the 
viral 3' LTR (10-12), the open reading  frame of which is 
capable of encoding a protein of ",~300 amino acids. Our lab- 
1  Abbreviations used in this  paper: MMTV, mouse mammary tumor virus; 
SAG, superantigen. 
oratory has recently shown that the open reading frame of 
the endogenous virus Mtv-7 encodes the Mls-1 protein and 
has named this gene Mtv-7 sag (12). Mls-1 is the prototype 
of the endogenous SAGs, as it elicits a strong in vitro prolifer- 
ative response in CD4 + T cells bearing the TCR V/3 6 or 
8.1 chains (13-16). Furthermore, it causes in vivo deletion 
of immature T cells bearing the appropriate TCR Vfl chain. 
Although the Mls molecules were functionally defined >20 
yr ago (17), it has not been possible to raise antibodies against 
this  strong T  cell stimulatory determinant, despite efforts 
of many research groups. Thus, biochemical analysis of this 
molecule has been impaired.  In this paper we describe the 
generation and characterization ofa mAb, 3B12, that is specific 
for Mls-1. 
Materials and Methods 
Mice.  DBA/2 (Mls-1  +,  H-2  d)  mice were purchased from 
Taconic Farms (Germantown, NY). B6.C-H-2  bm12 (bin12) mice 
were  bred at'the animal  facilities  at Tufts  University  School  of  Medi- 
cine. All mice were at least 6-8 wk of age. Armenian hamsters, 
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ment (West Roxbury, MA). 
Reagents and Media.  Complete medium was RPMI 1640 (Gibco 
Laboratories,  Grand Island, NY), supplemented with 2 mM t-glu- 
tamine, I mM Hepes, 50 #M 2-ME, 100/~g/ml penicillin, 100 U/ml 
streptomycin, and 10% FCS (Hazelton Biologics, Lenexa, KS). All 
supplements were purchased from JRH Biosciences (Lenexa, KS). 
TNM-FH medium (Sigma Chemical Co., St. Louis, MO) plus 10% 
FCS was used for propagation of Sf9 insect cells. PMA and Con A 
were purchased from Sigma Chemical Co. Protein A was purchased 
from Pharmacia Fine Chemicals (Uppsala,  Sweden). 
Cell Lines.  The V36 T cell hybridoma 18bbm19 (Mls-1 reac- 
tive, I-A  brat2 alloreactive) was provided by Dr. E. Palmer (Denver, 
CO). The VB6 T cell hybridoma RG17 (Mls-1 reactive), the Mls- 
1-expressing B cell hybridoma LBB.A (18), and its Mls-1- variant 
LBB.11 (4,  18) were gifts from Dr. A. Glasebrook (Indianapolis, 
IN). The VBS.1 + T cell hybridoma, KJ.16,  was provided by Dr. 
P. Marrack (Denver, CO). HT-2, Sf9, and P3X63-Ag8.653 cell lines 
were obtained from American Type Culture Collection (ATCC; 
Rockville, MD). Puro 14 is a cell line derived by transfection of 
LBB.11 with the Mtv-7 sag gene (12). This clone was chosen be- 
cause it expresses high levels of Mls-1  in functional assays. 
Antibodies.  The following mAb-producing B cell hybridomas 
were obtained from ATCC: RL172 (rat IgM) specific for murine 
CD4, TIB 211 (rat IgM) specific for murine CD8, and 1452Cll 
(hamster IgG) specific for murine CD3. T7.Tag antiserum was pur- 
chased from Novagen Inc. (Madison, WI). The mAb 2F9 (ham- 
ster IgG), which showed no detectable binding to Mls-1 § cells, 
was used  as a control Ab. 
Peptides.  Two peptides of 21 and 14 amino acids (peptide 21 
and peptide 14) were synthesized according to the deduced amino 
acid sequence of the 3' polymorphic region of the Mtv-7 sag gene 
(Fig.  1)  by  solid-phase  peptide  synthesis.  Peptide  21  (Ac- 
IAKILYNMKYTHGGRVGFDPF)  was  synthesized  by  Dr.  J. 
Garirpy (Toronto, Canada). An additional cysteine was added to 
the NH2 terminus of peptide 14 (CMKYTHGGRVGFDPF) for 
conjugation with carrier proteins and was synthesized at the Tufts 
Protein Synthesis facility. Peptide 14 was conjugated to KLH and 
OVA  (Sigma  Chemical  Co.),  using  m-maleimidobenzoyl-N- 
hydroxysuccinimide ester (Sigma Chemical Co.) by standard proce- 
dures (19). 
Immunization.  Armenian hamsters were immunized subcutane- 
ously with  50  /xg of KLH-peptide 14,  emulsified  in  Hunter's 
TiterMax  (CytRx  Corporation,  Norcross,  GA).  After  2  wk, 
boosters were given intraperitoneally in IFA (Sigma Chemical Co.). 
3 d before fusion, 20/zg of KLH-peptide 14 was administered in- 
travenously. 
Production and Screening of mAh  Fusions  were carried out by 
standard methods (20), using P3x63-Ag8.653 myeloma cells as a 
fusion partner. Hybrids secreting peptide-specific  mAbs were de- 
tected using an ELISA. Briefly, 96-well microtiter plates (Coming 
Laboratory Sciences Company, Coming, NY) were coated with 
OVA-peptide 14 (100 rig/well) to capture peptide-specific  mAbs. 
Alkaline phosphatase-conjugated anti-hamster IgG (Jackson Im- 
munoresearch, West Grove, PA) was added after washing. Enzyme 
activity was visualized by the addition ofp-nitrophenylphosphate 
(Kirkegaard & Perry Laboratories,  Inc., Gaithersburg, MD). The 
plates were read at 405 nm, using a microplate reader (MR 700; 
Dynatech, Chantilly, VA). 
Construction of Recombinant Transfer Vectors  and Production of Recom- 
binant Baculovirus.  The recombinant  transfer vector pVL1392- 
T7-TagSAG was constructed from the transfer vector pVL1392 (In- 
vitrogen,  San  Diego,  CA)  and  the  plasmid  pET-11aSAG (Fig. 
2), which was produced by PCR cloning of the full-length Mw-7 
sag gene from a genomic clone (12) into the BamHI site of pET- 
11a (Novagen Inc., Madison, WI), using the following primers: 
5' primer GGGGATCCATGCCGCGCCTGCAG, and 3' primer 
GGGCTAGCGGATCCGCAAGTAGACCTG. The correct orien- 
tation of the fragment was confirmed by restriction endonuclease 
digestion. The pET-11aSAG vector was digested with XbaI and 
EcoRV,  and the 1.2-kb  fragment containing the Mtv-7 sag gene 
was cloned into the XbaI/SmaI sites of the pVL1392 transfer vector. 
The recombinant baculovirus AcMNPV-T7-TagSAG was pro- 
duced by homologous recombination after cotransfection of the 
recombinant transfer plasmid pVL1392-T7.TagSAG with circular 
wild-type AcMNPV viral DNA (Invitrogen). Screening and en- 
richment for recombinant virus was carried out by three rounds 
of limiting dilution in 96-well tissue culture plates. Recombinant 
viruses were identified by dot-blot DNA hybridization of alkali-lysed 
cells (21), using  a 3zP-labeled probe of Mtv-7 sag.  The putative 
AcMNPV-T7.TagSAG viral isolates were used to infect Sf9 cells. 
Infected cell extracts were tested for expression of the T7.TagSAG 
protein by Western blot analysis, using a polyclonal antibody directed 
against  the  first  12  amino  acids of the T7 bacteriophage gene 
10 protein (Novagen). Final purification of the AcMNFV-T7-Tag- 
SAG  virus  was  achieved  by  two  rounds  of plaque  purifica- 
tion (21). 
Western Blotting.  Sf9 cells were infected at a multiplicity of in- 
fection of I and harvested after 60-96 h. Protein extracts were pre- 
pared by the solubilization of infected Sf9 cells in SDS-PAGE sample 
buffer with 2-ME and boiled for 5 min before electrophoresis on 
a 10% SDS-PAGE gel (22). The proteins were electrotransferred 
to a PVDF membrane (Millipore Corp., Bedford, MA) and probed 
with the 3B12 mAb or T7.Tag antiserum, as described previously 
(23).  Blocking experiments with peptide 21 were performed by 
preincubating the 3B12 mAb with peptide 21 (100/~g/ml) for 15 
min at room temperature. 
Purification of  Splenic B Lymphocytes and LPS Stimulation.  Single- 
cell suspensions of murine spleens were treated with Tris-buffered 
ammonium chloride to lyse RBC.  The cells were incubated for 
two cycles with a cocktail containing RL172 (anti-CD4), TIB 211 
(anti-CD8),  and guinea pig complement (Pelfreeze Biologicals, 
Rogers, AK) for 15 min at 37~  to eliminate T cells. The B cell-en- 
riched population was suspended  at 2  x  106 cells/ml and stimu- 
lated with LPS (10 #g/ml, Escherichia coli 055:B5; Sigma Chemical 
Co.) for 40-48 h. 
Flow Cytometry.  The Mls-l-specific,  protein G-purified mAb 
3B12 (Hamster IgG, 1 mg/ml) was biotinylated using the succini- 
mide ester of biotin, as described by Goding (24). Cells (5  x  105) 
in PBS, pH  7.2,  supplemented with  1%  FCS and 0.1%  NaN3 
(Sigma Chemical Co.), were incubated with biotinylated 3B12 mAb 
in the presence or absence of unconjugated 3B12 or peptide. The 
cells were washed and incubated with Streptavidin-conjugated PE 
(Southern Biotechnology Associates, Inc., Birmingham, AL). The 
cells were then analyzed by FACScan  |  (Becton Dickinson & Co., 
Mountain View,  CA). 
Stimulation of T Cell Hybridomas.  T cell hybridomas (2  x  104) 
were incubated with varying concentrations of B cell hybridomas 
(LBB.A, LBB.11) for 24 h at 37~  in an atmosphere of 5% CO2 
in the presence or absence of antibodies or peptides in a final volume 
of 200/.d in 96-well microtiter plates. For allostimulation, splenic 
B cells (5  x  105) from bm12 mice were incubated with 18bbm19 
(2  x  104) cells. For anti-CD3 assay, protein A (100 #g/ml) was 
coated on microtiter plates to capture the CD3 mAb. RG17 cells 
(2  x  104) were added to these wells in the presence  or absence 
of 3B12 or control mAbs. The IL-2 content of the resulting super- 
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Mtv  7  IYLGTGM-NF  WGKIFDYTEE  GAIAKILYNM  KYTHGGRVGF  DPF* 
Mtv  1  ........  IH  .  - .V.YNSR.  E.KRHIIEHI  .ALP* 
Mtv  8  .........  V  ..... H..K.  .  .V.RQ.EHI  SADTF.MSYN  G* 
Mtv  9  .........  V  ..... H..K.  .  .V.RL.EHI  SADTF.MSYN  G* 
Mtvll  .........  V  .....  H..K.  .  .V.RQ.EHI  SADTF.MSYM  G* 
MMTV  C3H  ........  H ......  H-.K.  .TV.GLIEHY  SPKTY.MSYY  E* 
MMTV  BR  6  .......  SSI  ..... H-.K.  RTVoALIEHY  SAKTY.MSYY  D* 
MMTV  GR  ........  H ....  V.H-.K  .....  GLIEHY  SAKTY.MSYY  D* 
Figure  1.  Compar/son of the deduced amino acid sequences of the 
COOH terminus of various MMTV sag-encoded molecules. 
natants from the above assays was determined in a bioassay using 
HT-2 cells. The proliferation of HT-2 cells after incubation with 
cell-free  supernatants  for  18-20  h  was  assessed by addition  of 
[3H]TdK (ICN Biochemicals,  Irvine, CA) during the last 6 h of 
culture, and the cells were harvested using a semiautomated cell 
harvester (PHD cell harvester; Cambridge Technology, Cambridge, 
MA).  [3H]TdK incorporation was measured by liquid scintillation 
counting (LS 7000; Beckman Instruments, Inc., Irvine, CA). Values 
are expressed as means  +  SD of counts per minute of quadrupli- 
cate determinations. 
RNA Pre~ration  and Northern  Blot  Analysis.  Total cellular RNA 
was extracted from lymphocytes using the guanidium isothiocyanate 
method (25). KNA (20 #g) was run on formaldehyde gels, blotted 
onto nylon membrane, and hybridized as previously described (26) 
to a 3zP-labeled  MMTV LTR probe (27). After exposure, the blot 
was stripped and rehybridized to a 32P-labeled GAPDH probe to 
evaluate  uniform mKNA loading. 
Results 
Production ofmA bs.  A comparison of the predicted amino 
acid sequences of various MMTV sag genes is shown in Fig. 1. 
Mtv-7 SAG differs completely from other MMTV  SAG se- 
quences in the last 20 amino acids. This sequence was, there- 
fore, used for synthesizing peptide  14 and for immunizing 
hamsters. Peptide specificity of the elicited serum antibodies 
was determined by an OVA-peptide  14 ELISA. Spleen cells 
Figure 3.  Western  blot analysis  ofbaculovims-infected  cell  extracts. Lanes 
I, 3, and 5 are wild-type baculovims-infected  SD cell extracts. Lanes 2, 
4, and 6 are AcMNPV-T7.TagSAG-infected  Sf9 cell extracts. Lanes 1 and 
2 show binding of the T7.Tag antiserum, lanes 3 and 4 show binding 
of the 3B12 mAb, and lanes 5 and 6 show the absence of binding of the 
3B12 mAb after preincubation with peptide 21. 
of hamsters with  a positive serum  titer were fused to my- 
eloma cells, resulting in "o500 hybridomas, of which 15 hy- 
bridomas secreted peptide 14-specific mAbs. These mAbs were 
further tested in a Western assay for binding to recombinant 
Mtv-7 SAG.  Only one of the  15 peptide  14-specific mAbs, 
designated as 3B12, reacted with the SAG protein in this assay 
(see below)  and  was  used for further  studies. 
Recognition of  Mtv-7 SAG by 3B12 mAh  To produce large 
amounts of the Mls-1  protein,  the Mtv-7 sag gene was ex- 
pressed in Sf9 insect cells, using the recombinant baculovirus 
AcMNPV-T7.TagSAG. A fusion protein was generated with 
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Xbal Sinai 
//  i\  Figure 2.  Construction  of the 
recombinant transfer vector pVL- 
1392-T7.TagSAG. The PCR pro- 
duct  of the  full-length Mtv-7 sag 
gene was first cloned into the bac- 
terial expression  vector  pET-11a.  The 
resulting  plasmid, pET-11aSAG, 
was  used to derive the  fragment 
T7.TagSAG, which was subcloned 
into the transfer vector pVL-1392. 
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Figure  4.  T  cell  proliferation 
assay. RG17,  18bbml9, or KJ.16 T 
cell hybridomas were cultured with 
the  stimulator  B  cell  hybridoma 
LBB.A. After 24 h, the supernatants 
were removed and tested in a bio- 
assay on IL-2-dependent HT-2 indi- 
cator cells. (a and b) In the presence 
or absence of 3B12 mAb and con- 
trol mAb; (c and d) 3B12 mAb in 
the presence or absence of peptide 21 
or peptide 14; (e) anti-CD3 stimula- 
tion in the presence or absence of 
3B12  or control mAb; (]) I-A  bml2 
allostimulation  by bml2 B cells in 
the presence or absence of 3B12 or 
control  mAb. 
tein to serve as an epitope tag (Fig. 2). The predicted fusion 
product is a protein of 37 kD. Two prominent bands corre- 
sponding  to 48 and 37 kD were observed in Western blot 
analysis of AcMNPV-T7.TagSAG-infected  Sf9 cell extracts, 
using the T7-Tag antiserum (Fig. 3). Extracts from cells in- 
fected with wild-type virus showed no significant binding 
of this antiserum.  The 3B12 mAb recognized  the 48- and 
37-kD products in AcMNPV-T7-TagSAG-infected Sf9 cells, 
although  the ability of 3B12 to bind to the 48-kD protein 
was  greatly reduced compared with the 37-kD  form.  No 
binding of 3B12 mAb to extracts of wild-type virus-infected 
cells was observed. Two other immunoreactive products were 
detected with the 3B12 mAb, namely a faint band of 33 kD 
and a prominent band of 27 kD (Fig. 3). These bands may 
represent breakdown products of the T7.TagSAG fusion pro- 
tein or indicate the use of alternate methionine initiation sites. 
The recognition  of the T7-TagSAG protein by 3B12 mAb 
was completely blocked by the addition of peptide 21 (Fig. 3). 
Inhibition of  Mls-l-specific T Cell Activation.  Two different 
T cell hybridomas bearing VB6 TClks (RG17 and 18bbm19) 
and a V~8.1 + T  cell  hybridoma  (KJ.16) were  stimulated 
with the Mls-l-expressing B cell hybridoma LBB.A. The ad- 
dition  of 3B12  mAb  to  the  cultures  resulted in  inhibi- 
tion of IL-2 production in response to Mls-1 stimulation (Fig. 
4). The inhibition was reversed by the addition of either pep- 
tide  14 or peptide 21.  On the other hand, the 3B12 mAb 
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Figure 5.  Surface expression of Mls-1 on LBB.A and puro 14. Indirect 
immunofluorescence was performed using biotinylated 3B12 and Strep- 
tavidin PE as second step.  (a) LBB.A and LBB.11 cells; (b) puro 14 in the 
presence or absence of unlabeled 3B12; (c) puro  14 in the presence or ab- 
sence of peptide  21. 
Figure  6.  T  cell proliferation  assay.  RG17  cells  were  cultured  with 
LBB.A, LBB.11,  or the Mtv-7 sag-transfected  LBB.11  cell line (puro 14), 
and Ib2-containing  supernatants were  assayed in a  HT-2  cell bioassay. 
transfectant, puro 14, which activated Mls-l-reactive T cells 
equally well as LBB.A (Fig.  6), stained brightly with 3B12 
mAb  (Fig.  5  b).  The  staining  of LBB.A and puro  14 cells 
was inhibited by the addition of unlabeled 3B12 mAb or pep- 
tide 21 (Fig.  5 c), confirming the specificity of the reaction. 
Primary  lymphocytes  from  four  Mls-1 +  mouse  strains, 
CBA/J, DBA/2, SWK, and NZB, could not be stained with 
3B12 mAb. Neither LPS activation of B cells,  nor stimula- 
tion of T  cells with Con A  or PMA,  resulted in a specific 
staining profile.  Furthermore, resting as well as PMA or Con 
A-activated  thymocytes were negative. 
Northern Blot Analysis.  Unstimulated B lymphocytes from 
DBA/2 mice showed the presence of LTR-specific mRNA, 
which was significantly increased upon LPS stimulation (Fig. 
7). Furthermore, LTK-specific  transcripts were detected only 
in PMA-stimulated CD8 + cells but not in CD4 + cells, Vir- 
tually no LTK-specific transcripts were observed in unstimu- 
lated  CD4 + or CD8 + cells. 
did not  block 11+-2 production  by the  18bbm19  T  cell hy- 
bridoma  in response to  allostimulation  with bm12 splenic 
B cells,  nor did it block II+-2 production  by T  cell hybrid- 
omas in response to activation with anti-CD3 mAb (Fig. 4). 
Surface Staining of  Mls-1 by 3B12 mAh  Biotinylated 3B12 
mAb stained the Mls-1 + B cell hybridoma LBB.A, as deter- 
mined  by flow cytometry,  whereas  LBB.11,  an  Mls-1  loss 
variant of LBB.A, was not stained (Fig.  5 a). The Mtv-7 sag 
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Figure  7.  Northern hybridization analysis of MMTV expression. Total 
RNA from the indicated cell types,  cultured in the presence or absence 
of stimulants for  16-18 h,  was  subjected to electrophoresis,  transferred 
to nylon membrane, and probed with an MMTV-LTR probe (top),  or the 
GAPDH  probe (bottom). Analysis of unseparated thymocytes revealed the presence 
of LTR-specific mRNA, even in unstimulated cells (Fig. 7). 
While Con A  stimulation leads to a small increase in the 
amount of 3.6- and 1.7-kb MMTV transcripts in the thymo- 
cytes, PMA stimulation caused a substantial increase in the 
level of these two mRNA species. 
Discussion 
Since the discovery of the open reading frame in the U3 
region of the MMTV LTR., virologists have been searching 
for the product of this gene. Racevskis (28) generated a pep- 
tide antiserum directed against a conserved hydrophilic re- 
gion of the open reading frame gene product and was able 
to immunoprecipitate in vitro translation products of this 
gene. However, with the exception of phorbol ester-treated 
T cell thymomas, which have amplified MMTV, no protein 
expression was detected. Similar negative results were ob- 
tained by many other research groups. More recently, Bran&- 
Carlson and Butel (29) have raised antisera against a recom- 
binant baculovirus product of the infectious MMTV C3H 
sag gene. While these investigators were able to visualize the 
recombinant protein from infected Sf9 insect cells in Western 
blots, no protein was detected in mammary tumor cells or 
lymphocytes. Numerous immunologists have attempted in 
vain to raise antisera to Mls-1 by immunization with Mls-1- 
expressing lymphocytes. These observations indicate that the 
MMTV SAG is expressed in minute quantities and, although 
efficiently recognized by T  cells, is insufficient for eliciting 
an antibody response. Therefore, standard biochemical tests 
may not be sensitive  enough to detect the low level of ex- 
pressed SAG molecules. 
We have previously shown that Mtv-7 sag encodes Mls-1 
(12). The comparison of the predicted amino acid sequences 
of the various MMTV sag genes suggests that the TCR VB 
specificity is conferred by the COOH terminus (see Fig.  1), 
since the major polymorphism is restricted to this part of 
the molecule. It has recently been reported that the MMTV 
SAG is a type II transmembrane glycoprotein, because the 
COOH  terminus is extracellular, as deduced from in vitro 
translation studies in the presence of microsomes (30-32). 
We  have,  therefore,  synthesized peptides  specific  for  the 
COOH-terminal region of the Mtv-7 SAG, to produce Mls- 
1-specific antibodies. 
Among the 15 mAbs that reacted with the Mtv-7 SAG- 
specific peptide (peptide 14) in an ELISA, only one was able 
to detect the baculovirus-derived  recombinant Mtv-7 SAG pro- 
tein in Western blots. This mAb, called 3B12, reacted with 
48- and 37-kD products (Fig. 3), which were also visualized 
with the T7.Tag antiserum. It is likely that the 48-kD product 
is a glycosylated form of the recombinant molecule, in agree- 
ment with previous reports (29),  since the overall structure 
of the MMTV sag gene is very conserved. The 37-kD band, 
on the other hand, may represent the unglycosylated precursor 
molecule (29). Unlike the T7.Tag antiserum, the 3B12 mAb 
recognizes the 37-kD molecule more efficiently than the 48- 
kD protein. A possible explanation is that the Sf9 insect cell 
glycosylation interferes with 3B12 binding. Two additional 
bands of 33  and 27 kD,  respectively, recognized by 3B12, 
are either breakdown products of the T7.TagSAG fusion pro- 
tein, or products that indicate the use of alternate methio- 
nine initiation sites,  since they are not seen in cell extracts 
from wild-type-infected Sf9 cells. These bands are not de- 
tected with the T7.Tag antiserum, which is directed against 
an NH2-terminal determinant. The addition of peptide 21 
abrogated 3B12 binding, confirming the specificity of the 3B12 
mAb for the T7-TagSAG protein. 
To test whether this mAb could detect the native Mls-1 
molecule expressed on murine B cells, we carried out blocking 
experiments, using TCR V~36  + and V38.1 + T cell hybrid- 
omas as responders and Mls-l-expressing B cell hybridomas 
as stimulator cells. While this interaction was blocked by the 
addition of 3B12 mAb, no effect was seen on allorecognition 
or anti-CD3 stimulation of the same T cell hybridoma. Since 
the peptide sequence used for immunization is unique to the 
Mtv-7-derived SAG molecule, no blocking of any other SAG 
responses is  expected.  Furthermore,  the specificity of the 
blocking reaction was again confirmed by the addition of pep- 
tide 14 or peptide 21, which eliminated the inhibition of IU2 
production. 
The experiments outlined so far confirm the Mls-1 specificity 
of the 3B12 mAb. It was of interest, therefore, to carry out 
immunofluorescence experiments.  The  LBB.A  B  cell hy- 
bridoma, which stimulates Mls-l-reactive T cells efficiently, 
was clearly positive for surface staining with 3B12, compared 
with the Mtv-7 loss variant of LBB.A (LBB.11), which was 
negative. To unequivocally prove that this staining reaction 
was specific for Mls-1, we tested Mtv-7 sag gene transfectants 
of LBB.11 and found that some of these had a bright staining 
profile. 
It is well documented that B cells (33, 34) and CD8 + T 
cells (35), but not CD4 + T cells, are capable of stimulating 
an Mls-l-specific response. This stimulatory capacity is fur- 
ther enhanced after in vitro culture with various mitogens 
(28,  36).  Our results confirm the above observations, since 
MMTV-specific steady-state mRNA was detected in unstimu- 
lated and LPS-stimulated B cells. Furthermore, only PMA- 
treated CD8 + , but not CD4 + , ceils revealed the presence 
of MMTV-specific mRNA. When these lymphocyte subsets 
were tested for staining with the 3B12 mAb, they were all 
negative,  even after in  vitro  stimulation  with  mitogens. 
Overall, we have repeatedly tested four Mtv-7-positive mouse 
strains of various H-2 types and could see no difference in 
the staining profile compared to lymphocytes from Mtv-7- 
negative strains.  Furthermore, all thymocyte subsets  tested 
were negative, although they have considerable MMTV-specific 
mRNA, as detected in Northern analyses. In agreement with 
this finding, we observed many Mtv-7 sag transfectants that 
showed good functional Mls-1 reactivity in terms of T  cell 
stimulation, but were negative when stained with the 3B12 
mAb. On the other hand, their Mls-1  stimulatory capacity 
could be blocked with this mAb (data not shown). 
Overall, these experiments indicate that though Mls-1 ex- 
pression is minimal, it is sufficient to cause T cell stimula- 
356  Mls-l-specific  Monoclonal Antibody tion, but not for detection with this mAb. This is a general 
feature of antigenic determinants recognized by T  cells,  as 
it  has  been  shown  that  minute  quantities  of peptide  are 
sufficient for T  cell stimulation (37, 38). The availability of 
Mtv-7 sag transfectants expressing high levels of Mls-1 pro- 
tein will now facilitate biochemical analysis of this molecule. 
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